减毒活嵌合日本脑炎疫苗作为SA14-14-2减毒活疫苗初次接种后的加强剂量的免疫原性：泰国儿童的IV期研究。
Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine as a Booster Dose After Primary Vaccination With Live Attenuated SA14-14-2 Vaccine: A Phase IV Study in Thai Children.
作者信息
Sricharoenchai Sirintip, Lapphra Keswadee, Chuenkitmongkol Sunate, Phongsamart Wanatpreeya, Bouckenooghe Alain, Wittawatmongkol Orasri, Rungmaitree Supattra, Chokephaibulkit Kulkanya
机构信息
From the *Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; †Sanofi Pasteur, Bangkok, Thailand; and ‡Clinical Sciences, Sanofi Pasteur, Singapore.
出版信息
Pediatr Infect Dis J. 2017 Feb;36(2):e45-e47. doi: 10.1097/INF.0000000000001395.
This single-group study investigated the immunogenicity and safety of a booster dose of the recently licensed live attenuated chimeric Japanese encephalitis vaccine in 50 healthy children (1-5 years old) who were primed with the live attenuated SA14-14-2 vaccine. A strong anamnestic response was induced 28 days postbooster: geometric mean titer, 9144 (95% confidence interval: 7365-11353); and seroprotection rate, 49 of 49 (100%) children.
这项单组研究调查了近期获批的减毒活嵌合日本脑炎疫苗加强剂量在50名健康儿童（1至5岁）中的免疫原性和安全性，这些儿童已接种过减毒活SA14-14-2疫苗进行基础免疫。加强免疫后28天诱导出强烈的回忆反应：几何平均滴度为9144（95%置信区间：7365-11353）；血清保护率为49/49（100%）名儿童。
Zotero 插件